Login / Signup

Performance assessment of DNA sequencing platforms in the ABRF Next-Generation Sequencing Study.

Jonathan FooxScott W TigheCharles M NicoletJustin M ZookMarta Byrska-BishopWayne E ClarkeMichael M KhayatMedhat MahmoudPhoebe K LaaguibyZachary T HerbertDerek WarnerGeorge S GrillsJin JenShawn E LevyJenny XiangAlicia AlonsoXia ZhaoWenwei ZhangFei TengYonggang ZhaoHaorong LuGary P SchrothGiuseppe NarzisiWilliam FarmerieFritz J SedlazeckDon A BaldwinChristopher E Mason
Published in: Nature biotechnology (2021)
Assessing the reproducibility, accuracy and utility of massively parallel DNA sequencing platforms remains an ongoing challenge. Here the Association of Biomolecular Resource Facilities (ABRF) Next-Generation Sequencing Study benchmarks the performance of a set of sequencing instruments (HiSeq/NovaSeq/paired-end 2 × 250-bp chemistry, Ion S5/Proton, PacBio circular consensus sequencing (CCS), Oxford Nanopore Technologies PromethION/MinION, BGISEQ-500/MGISEQ-2000 and GS111) on human and bacterial reference DNA samples. Among short-read instruments, HiSeq 4000 and X10 provided the most consistent, highest genome coverage, while BGI/MGISEQ provided the lowest sequencing error rates. The long-read instrument PacBio CCS had the highest reference-based mapping rate and lowest non-mapping rate. The two long-read platforms PacBio CCS and PromethION/MinION showed the best sequence mapping in repeat-rich areas and across homopolymers. NovaSeq 6000 using 2 × 250-bp read chemistry was the most robust instrument for capturing known insertion/deletion events. This study serves as a benchmark for current genomics technologies, as well as a resource to inform experimental design and next-generation sequencing variant calling.
Keyphrases
  • single molecule
  • circulating tumor
  • single cell
  • high resolution
  • copy number
  • cell free
  • endothelial cells
  • mass spectrometry
  • high density
  • circulating tumor cells
  • dna methylation
  • affordable care act